Skip to main content

Table 4 Factors associated with mortality among patients who completed follow-up (N = 580)a

From: Drug-resistant Enterobacteriaceae colonization is associated with healthcare utilization and antimicrobial use among inpatients in Pune, India

Clinical Factor

Survived, N = 546, n (%)

Died, N = 34, n (%)

Unadjusted OR (95% CI)

p-value

Adjusted ORb (95% CI)

p-value

Male sex

321 (59)

23 (68)

1.5 (0.7–3.4)

0.37

–

–

Child < 12 years

267 (49)

11 (32)

0.5 (0.2–1.1)

0.08

0.2 (0.1–0.4)

< 0.01

Income < 5000 INR / month

197 (36)

15 (44)

1.4 (0.6–3)

0.36

–

–

Diabetes

18 (3)

1 (3)

0.9 (0–6)

1

–

–

HIV

56 (10)

7 (21)

2 (0.6–5.7)

0.17

–

–

Diarrhea

110 (20)

9 (26)

1.4 (0.6–3.3)

0.38

–

–

Cough

278 (51)

13 (38)

0.6 (0.3–1.3)

0.16

–

–

ICU admission

96 (18)

19 (56)

6.8 (3.1–15.6)

< .01

14.7 (6.1–36.9)

< 0.01

Admission ceftriaxone-resistant EB colonization

52 (10)

2 (6)

0.6 (0.1–2.4)

0.76

–

–

Follow-up ceftriaxone-resistant EB colonization

53 (10)

8 (24)

2.9 (1.1–6.9)

0.02

2.4 (0.9–6.0)

0.06

Acquisition of ceftriaxone-resistant EB colonization

37 (7)

6 (18)

2.8 (0.9–7.7)

0.04

–

–

  1. OR odds ratio, INR Indian Rupees, ICU intensive care unit, EB Enterobacteriaceae
  2. aMortality data was not available for 40 (6%) of patients who completed follow-up perirectal swab collection
  3. bAdjusted for child < 12 years, ICU admission, and colonization with ceftriaxone-resistant EB at follow-up